"Fresenius Medical Care Increases Profit in Fourth Quarter Thanks to Cost Savings Despite Stagnant Sales and Forecasts Revenue and Earnings Growth for This Year. The German dialysis company announced on Tuesday that it achieved a net profit of 188 million euros ($202.7 million) in the quarter, compared to 139 million euros in the same period last year. Revenue remained nearly unchanged at 4.99 billion euros, but adjusted for a 7.4% increase at constant currency rates. Adjusted operating income increased by 14% to 555 million euros, according to the company. The savings from the '2025' program are above plan, the company said."
Analysts expected Fresenius Medical Care to record sales of 4.94 billion euros, an adjusted operating result of 546 million euros, and a net profit of 176 million euros, according to consensus estimates provided by the company. For 2024, the company forecasted sales growth in the low to mid-single-digit percentage range and operating income growth in the mid to high teens range, both at constant currencies and excluding special effects. The Executive Board increased the dividend for 2023 by 6% to 1.19 euros per share.
While many companies struggled with financial challenges due to the effects of the COVID-19 pandemic, Fresenius Medical Care managed to achieve impressive results in the fourth quarter. Thanks to the implementation of cost-saving measures as part of their 2025 program, the company was able to record a rise in net profit despite stagnant sales. Particularly encouraging is the fact that the savings even exceeded the company's expectations.
The steady increase in profits and effective cost control show that Fresenius Medical Care is well-positioned to continue its success in the future. This is supported by the forecast for this year, which predicts further revenue and earnings growth. This demonstrates the company's confidence in its business model and its ability to succeed even in challenging times.
To further reward its shareholders, the company also increased the dividend for 2023. This sends a positive signal to investors and highlights the strength of Fresenius Medical Care's financial position.
The heading translated to English is:
"The company plans to continue achieving steady and sustainable growth for the future. With a focus on innovation and efficiency, Fresenius Medical Care aims to improve the treatment of kidney diseases worldwide. Combined with the company's solid financial strategy and strong management team, it is well-positioned to remain successful in the future and to strengthen its position as a market leader."
